Scholar Rock Holding Corp (SRRK)

Apr 18, 2025, 4:15 PM EDT - 8 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 7:30 AM EDT - 4 weeks ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 17, 2025, 12:21 PM EDT - 5 weeks ago

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Mar 16, 2025, 7:00 PM EDT - 5 weeks ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 27, 2025, 1:23 PM EST - 2 months ago

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 2 months ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 25, 2025, 4:15 PM EST - 2 months ago

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 21, 2025, 8:00 AM EST - 2 months ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 10, 2025, 8:00 AM EST - 2 months ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Jan 30, 2025, 8:37 AM EST - 3 months ago

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Jan 29, 2025, 8:05 AM EST - 3 months ago

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Jan 29, 2025, 8:00 AM EST - 3 months ago

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Jan 15, 2025, 2:23 PM EST - 3 months ago

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Jan 8, 2025, 4:00 PM EST - 3 months ago

Scholar Rock Highlights 2025 Strategic Priorities

Jan 2, 2025, 8:00 AM EST - 4 months ago

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 11:51 AM EST - 5 months ago

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Nov 12, 2024, 11:09 AM EST - 5 months ago

Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 5 months ago

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

Nov 4, 2024, 8:00 AM EST - 6 months ago

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

Nov 1, 2024, 8:00 AM EDT - 6 months ago

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Oct 31, 2024, 8:00 AM EDT - 6 months ago

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

Oct 25, 2024, 8:22 AM EDT - 6 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

IBRX

Oct 22, 2024, 8:00 AM EDT - 6 months ago

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Oct 8, 2024, 11:08 PM EDT - 7 months ago

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Oct 7, 2024, 10:10 PM EDT - 7 months ago

Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial

Oct 7, 2024, 5:29 PM EDT - 7 months ago

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Oct 7, 2024, 4:09 PM EDT - 7 months ago

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Oct 7, 2024, 3:28 PM EDT - 7 months ago

Dow Jones, S&P 500 fall amid rising oil prices; Scholar Rock jumps 300%, Apple and insurance stocks dip

Oct 7, 2024, 12:00 PM EDT - 7 months ago

Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher

Oct 7, 2024, 10:23 AM EDT - 7 months ago

Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year

Oct 7, 2024, 8:20 AM EDT - 7 months ago

Scholar Rock's stock soars more than 200% on positive trial of treatment for spinal muscular atrophy

Oct 7, 2024, 7:00 AM EDT - 7 months ago

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Sep 10, 2024, 8:00 AM EDT - 8 months ago

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Sep 4, 2024, 8:00 AM EDT - 8 months ago

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Aug 26, 2024, 12:00 PM EDT - 8 months ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP GPCR VKTX

Aug 8, 2024, 7:00 AM EDT - 9 months ago

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

Jul 23, 2024, 8:00 AM EDT - 9 months ago

Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jun 24, 2024, 7:00 AM EDT - 10 months ago

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Jun 3, 2024, 4:00 PM EDT - 11 months ago

Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting

May 28, 2024, 8:00 AM EDT - 11 months ago

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

May 14, 2024, 8:00 AM EDT - 1 year ago

Scholar Rock to Host Investor Day on May 22, 2024

May 7, 2024, 7:00 AM EDT - 1 year ago

Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

Feb 15, 2024, 8:00 AM EST - 1 year ago

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Feb 6, 2024, 8:00 AM EST - 1 year ago

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Jan 25, 2024, 8:00 AM EST - 1 year ago

Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia

Jan 23, 2024, 8:00 AM EST - 1 year ago

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Jan 12, 2024, 5:32 AM EST - 1 year ago

Scholar Rock: Solid Data And Good Prospects

Jan 4, 2024, 8:00 AM EST - 1 year ago

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024